Welcome to the November issue of International M&A’s newsletter.
First, we appreciate the many referrals you all have provide as we grow our organization. And, as we grow, we receive questions related to our services and what we see happing in the global markets. In this issue, we will focus on addressing some of the frequently asked questions and share insights into the international markets. We look forward to sharing more in the coming months and welcome your comments.
In meeting with many of you, we receive many questions. The following addresses some of the more frequently asked questions:
FAQ: What kind of investors do you work with?
We work with a variety of investors including strategic and institutional investors, and family offices around the world. Investments start at $50 million. We currently do not work with individual investors.
International Market Update: Things that caught my eye
Every day we work with people in all parts of the world and make it our goal to be aware of the global movement assist our clients in capturing the right opportunities and get them to a new foreign market in a smooth and efficient manner. The following news items are of interest to many of our clients.
China’s Drug Market Is Opening Up: Beijing’s health-care reforms are giving global pharmaceutical companies better access to the world’s second-largest drug market
Comments: We currently represent US and EU pharmaceutical and medical device companies entering the China market. Through a holistic approach we provide a variety of solutions for our clients: product sale, licensing agreement, and M&A. Please contact [email protected] directly for medical products ready for the China market.
Irish biopharmaceutical company Alkermes has agreed to buy US-based neuroscience-focused firm Rodin Therapeutics under a deal worth up to $950m
Indian generic firm again fails in Japan; Lupin sells Kyowa
AstraZeneca to Raise $1 Billion to Invest in China Startups
Comments: China is starting to allow more industries access to foreign direct investments, including pharma, energy, and financial sectors.
New policy measures in Beijing have opened China to drug multinationals and helped Chinese biotechs attract investors
China: TOTAL and Zhejiang Energy Group Join Forces to Develop the Growing Low Sulphur Marine Fuel Market
Gas 2019 Analysis and Forecasts 2024
Comments: After another record year, global demand for natural gas is set to keep growing over the next five years, driven by strong consumption in fast-growing Asian economies and supported by the continued development of the international gas trade. With 2019 ending, read more from the IEA’s Gas 2019 Analysis and Forecasts 2024.
Southeast Asia May Become Net Fossil Fuel Importer in Coming Years: IEA
Battle for Madrid Bourse Erupts; SIX Bids, Euronext in Talks
Jingye to invest £1bn and save ‘thousands of British Steel jobs’